Table 7 The results of one-way sensitivity analysis

Cost of Trastuzumab

705.83

1075.93

1058.74

Increase

18797.48058

31508.2107

Utility PFS¹

0.648

0.81

0.972

Decrease

16516.55064

22613.22765

Cost FOLFOX

221.26

272.47

331.88

Decrease

16118.78074

19900.50217

Utility PP²

0.48

0.6

0.72

Decrease

18283.65661

19970.6114

Cost PFS

76.49

95.62

114.74

Increase

18869.15424

19310.60623

Discount rate

0.003

0.004

0.005

Increase

18891.33631

19289.49341

Cost PP

94.1

117.62

141.15

Increase

18986.21833

19193.70165

Cost Thrombocytopenia

51.36

64.2

77.03

Increase

19064.36882

19115.48714

P³ Thrombocytopenia_FOLFOX

0.036

0.045

0.054

Decrease

19081.07004

19094.37189

P Thrombocytopenia_trastuzumab

0.036

0.045

0.054

Increase

18957.6584

18970.96026

P Neutropenia_trastuzumab

0.0928

0.116

0.1392

Increase

19085.27246

19090.17016

P Neutropenia_FOLFOX

0.0928

0.116

0.1392

Decrease

19087.48909

19092.38679

Disutility BD⁴

-0.0948

-0.079

-0.0632

Increase

19088.12561

19091.75062

Cost Neutropenia

7.34

9.17

11

Increase

19089.49558

19090.3803

P Anemia_FOLFOX

0.0216

0.027

0.0324

Decrease

19093.97429

19094.8358

P Anemia_trastuzumab

0.0216

0.027

0.0324

Increase

19086.95456

19087.81607

Cost Anemia

5.55

6.93

8.32

Decrease

19089.55394

19090.31918

P Gastrointestinal_FOLFOX

0.0504

0.063

0.0756

Decrease

19089.31912

19089.78324

P Gastrointestinal_trastuzumab

0.0504

0.063

0.0756

Increase

19090.1479

19090.61201

Cost Gastrointestinal

1.28

1.6

1.92

Decrease

19089.92689

19089.94899

Disutility AE⁵

-0.18

-0.15

-0.12

Increase

19089.93794

19089.93794